{"filings":[{"id":77923,"accession_number":"0001493152-26-022875","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2026-05-14T12:00:42+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biofrontera Q1 revenue up 17% to $10.1M; gross margin 80%; PDUFA for sBCC set Sept 2026","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $10.1M (+17% YoY); gross margin 80% (vs 62% Q1 2025) from new earnout structure.","Net loss $4.8M ($0.41/shr) vs $4.2M ($0.47/shr); operating loss improved to $4.3M from $4.5M.","Adjusted EBITDA -$3.6M vs -$4.4M; cash consumption near zero; cash $6.3M vs $1.8M Q1 2025.","FDA accepted sNDA for Ameluz PDT for superficial BCC; PDUFA target date Sept 28, 2026.","Positive Phase 3 AK results (primary endpoint met) and Phase 2b acne data (58% lesion reduction); regained Nasdaq compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110138,"accession_number":"0001493152-26-011545","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2026-03-19T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biofrontera reports record Q4 revenue $17.1M, net income $5.6M; full-year 2025 revenue up 12% to $41.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue $17.1M, up 36% YoY; net income $5.6M vs. net loss $1.4M in Q4 2024.","Full-year 2025 revenue $41.7M, up 12% YoY; net loss narrowed to $10.5M from $17.7M.","Gross margin improved to 82.4% in Q4 (from 58.0%) due to new earnout structure after asset purchase from Biofrontera AG.","Adjusted EBITDA was $4.9M in Q4 vs. -$1.4M; full-year Adjusted EBITDA -$10.6M vs. -$15.3M.","Pipeline: PDUFA date for sBCC September 2026; positive Phase 3 AK results; Phase 2b acne data."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110137,"accession_number":"0001493152-26-009321","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2026-03-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biofrontera reports positive Phase 2b results for Ameluz PDT in moderate-to-severe acne; plans FDA meeting in Q3 2026","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Phase 2b study: 3-hour Ameluz incubation achieved 57.97% reduction in inflammatory lesions vs 36.51% for vehicle.","25% of Ameluz patients met mIGA co-primary endpoint (clear/almost clear) vs 21.4% with vehicle.","Safety profile consistent with prior PDT; most treatment-related AEs were mild-to-moderate burning and pruritus.","85.7% of 3-hour Ameluz patients would choose PDT again; 71.4% rated esthetic outcome good/very good.","Company to present data to FDA in Q3 2026 to discuss next steps for acne vulgaris indication."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110136,"accession_number":"0001493152-26-008136","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"PTAB finds Sun Pharma’s patent '028 unpatentable, a win for Biofrontera in patent dispute","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["PTAB issued Final Written Decision on Feb 23, 2026, invalidating all challenged claims of Sun's U.S. Patent No. 11,697,028.","Sun may request rehearing, petition the Director, or appeal to the Federal Circuit.","Decision does not affect the separate '512 patent; that IPR petition was denied on administrative grounds.","Impact on parallel District Court and ITC proceedings is not yet determinable."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110135,"accession_number":"0001493152-26-005717","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2026-02-09T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biofrontera Phase 3 Ameluz® PDT meets primary endpoint for AK on extremities/neck/trunk","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Complete clearance 45.6% (Ameluz®) vs 16.7% (vehicle), p<0.0003 in FAS.","Per protocol set complete clearance 53.2% vs 22.2% (p<0.001).","Study enrolled 172 patients randomized 4:1; lesion clearance rate 73.1% (FAS).","Cosmetic outcomes: 75.2% rated 'good/very good'; 86.3% would choose PDT again.","sNDA submission to FDA planned for Q3 2026 based on these positive results."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110134,"accession_number":"0001493152-26-001959","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2026-01-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biofrontera reports record preliminary Q4 2025 revenue of $17.0-17.5M, up ~35-39% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 preliminary revenue $17.0-17.5M, highest quarterly revenue in history, YoY growth 35-39%.","Full year 2025 preliminary revenue $41.5-42.0M, YoY growth 11-13%.","CEO cites strong Ameluz sales execution and December pricing adjustment driving record quarter.","Recent transaction with Biofrontera AG expected to improve gross margin profile and strengthen finances.","Final Q4 and full year 2025 results to be reported in March 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.04,"consensus_revenue_estimate":null,"consensus_revenue_actual":41705000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":110133,"accession_number":"0001493152-26-000823","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2026-01-07T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biofrontera receives Nasdaq deficiency notice for bid price below $1.00 for 34 days","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notice on Dec 31, 2025: common stock not compliant with Listing Rule 5550(a)(2) due to closing bid below $1.00.","Company has 180 calendar days, until June 30, 2026, to regain compliance by closing at $1.00+ for 10 consecutive days.","If not cured, company may qualify for second 180-day period by meeting other continued listing standards and indicating intent to cure via reverse stock split.","Failure to cure could lead to delisting; company plans to monitor and consider available options.","No immediate impact on trading; Biofrontera common trades on Nasdaq under symbol BFRI."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126681,"accession_number":"0001493152-25-022133","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biofrontera Q3 revenue $7.0M, net loss $6.6M; closes Ameluz asset purchase","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 2025 revenues $7.0M (down 22% YoY); 9-month revenues stable at $24.6M vs $24.8M.","Net loss $6.6M vs $5.7M in Q3 2024; Adjusted EBITDA -$6.0M vs -$4.6M.","Closed purchase of all U.S. assets for Ameluz and RhodoLED from Biofrontera AG; earnout reduced to 12-15% of net sales.","Divested Xepi antibiotic cream to Pelthos Pharmaceuticals for $3M closing plus up to $6M milestones.","Cash $3.4M at Sep 30; additional $2.5M received in Oct; runway extended by asset purchase and divestiture."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.67,"consensus_revenue_estimate":null,"consensus_revenue_actual":24605000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126680,"accession_number":"0001493152-25-021525","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-11-10T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Biofrontera regains Nasdaq compliance on stockholders' equity and bid price rules","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Received Nov 4 notice from Nasdaq confirming compliance with Rule 5550(b)(1) (stockholders' equity).","Received Nov 6 notice confirming compliance with Rule 5550(a)(2) (minimum bid price ≥$1.00 for 11 consecutive days).","Company previously disclosed deficiencies on May 21 and May 8, 2025 respectively.","Nasdaq notes company may be subject to delisting if fails to evidence compliance upon next periodic report."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126679,"accession_number":"0001493152-25-021189","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-11-07T23:59:59+00:00","items":["1.01","2.01","7.01","9.01"],"status":"ready","headline":"Biofrontera sells Xepi® license to Pelthos for up to $10M; receives $3M at close","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Sold US license of Xepi® (ozenoxacin) cream to Pelthos Therapeutics for up to $10M total consideration.","Received $3M cash at closing; additional $1M due upon availability of commercial product.","Up to $6M in milestones: $3M each upon achieving $10M and $15M annual net sales of Xepi®.","Company expects proceeds to fund operations to profitability, supporting Ameluz® PDT franchise.","Transaction bolsters cash position after recent restructuring of agreement with Biofrontera AG."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126678,"accession_number":"0001493152-25-019370","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-10-24T23:59:59+00:00","items":["1.01","2.01","3.02","8.01","5.03","9.01"],"status":"ready","headline":"Biofrontera closes acquisition of U.S. rights to Ameluz; raises $2.5M in Series C preferred","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired all U.S. rights to Ameluz and RhodoLED from former parent Biofrontera AG per Asset Purchase Agreement dated Oct 20, 2025.","Earnout replaces prior transfer pricing model: 12% of U.S. net sales ≤$65M, 15% if >$65M.","Closed second tranche of Series C Preferred Stock, raising $2.5M gross; total offering now $11M.","Believes stockholders' equity now exceeds $5M, regaining compliance with Nasdaq minimum equity requirement.","Proceeds from preferred stock to fund acquisition and transfer costs and general corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":126677,"accession_number":"0001493152-25-019006","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-10-23T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biofrontera closes purchase of Ameluz/RhodoLED US assets, reduces earnout to 12-15%","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired all U.S. assets and rights to Ameluz and RhodoLED, including NDA, patents, manufacturing, and personnel.","New earnout structure: 12% of net sales up to $65M, 15% above; replaces prior 25-35% perpetual payment.","Closing released final $2.5M of $11M financing led by existing investors Rosalind Advisors and AIGH.","Biofrontera AG receives 10% post-money equity stake in Biofrontera Inc., aligning long-term interests.","Company expects full asset and personnel transfer by late Q4 2025 or early Q1 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143465,"accession_number":"0001493152-25-014281","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-09-19T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biofrontera stockholders approve reverse stock split and preferred stock conversion proposals","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Reverse stock split amendment approved (7,161,214 for, 1,239,537 against) to maintain Nasdaq minimum bid price compliance.","Issuance of common stock upon conversion of Series C Preferred Stock and elimination of voting limits approved (3,470,432 for).","Issuance of common stock upon conversion of Series D Preferred Stock and elimination of voting limits approved (5,053,120 for).","Adjournment proposal approved (7,371,647 for) to allow further solicitation if needed for other proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143464,"accession_number":"0001641172-25-023598","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-08-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biofrontera Q2 rev $9.0M (+15%); net loss $5.3M; restructures AG deal, new royalty 12-15%","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2025 revenue $9.0M (up 15% YoY); net loss $5.3M vs $0.3M in Q2 2024.","Adjusted EBITDA negative $5.1M vs negative $4.7M; cash $7.2M at June 30.","Acquired US IP and NDA from Biofrontera AG; new Ameluz royalty 12%/15% vs prior 25-35%.","Received $11M additional funding; US patent for revised Ameluz granted through 2043."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.05,"consensus_revenue_estimate":null,"consensus_revenue_actual":17617000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143463,"accession_number":"0001641172-25-023006","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-08-11T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Biofrontera appoints George Jones as Chief Commercial Officer effective August 25, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["George Jones named CCO of Biofrontera (Nasdaq: BFRI), bringing over 25 years of commercial leadership in pharmaceuticals and biotech.","Compensation: $315,000 base salary, up to 50% bonus, and at least 100,000 stock options with one-year vesting per year over three years.","Jones previously served as COO at UpScriptHealth, where partnership revenues increased more than threefold, and held VP roles at Currax Pharmaceuticals and Pernix Therapeutics.","Appointment follows Biofrontera's agreement to acquire US rights to Ameluz and RhodoLED from Biofrontera AG, reducing royalty from 25%-35% to 12%-15% of net sales.","Company states the management strengthening and improved royalty terms will bring it significantly closer to cash break-even."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143461,"accession_number":"0001641172-25-019884","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K/A","filed_at":"2025-07-16T23:59:59+00:00","items":["9.01"],"status":"ready","headline":"Biofrontera to acquire US Ameluz/RhodoLED rights; royalty 12-15%, 10% equity stake","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront EUR 2,593,750 payment due June 30, 2025; condition to raise $8.5M preferred equity by same date.","Royalty on US net sales: 12% up to $65M revenue, 15% above; minimum 80,000 tubes/year penalty clause.","Sellers receive preferred stock convertible to 10% of fully diluted Biofrontera Inc. common equity.","Sellers get 1-2 board seats as long as they hold preferred stock; term sheet void if conditions unmet.","Buyer assumes all US supply costs and legal defense; stockholder vote required for conversion rights."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":143462,"accession_number":"0001641172-25-017285","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-07-01T23:59:59+00:00","items":["1.01","3.02","3.03","5.03","9.01"],"status":"ready","headline":"Biofrontera acquires U.S. rights to Ameluz/RhodoLED from Biofrontera AG; raises $11M via Series C preferred","summary_kind":"llm","event_type":"m_and_a","confidence":"high","bullets":["Acquired all U.S. rights to Ameluz and RhodoLED from Biofrontera AG; will pay royalty of 12% or 15% based on $65M revenue threshold.","Biofrontera AG receives 3,109 Series D Convertible Preferred shares (10% post-money equity stake) as part of consideration.","Private placement of up to 11,000 Series C Preferred shares at $1,000 each for gross proceeds of up to $11.0M to fund the deal.","Initial closing of $8.5M expected July 1, 2025; subsequent closing of $2.5M expected by September 30, 2025.","Conversion and voting rights of both preferred series are subject to stockholder approval under Nasdaq rules."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161655,"accession_number":"0001641172-25-017052","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-06-30T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biofrontera acquires US Ameluz/RhodoLED rights, cuts royalty to 12%, gets $11M financing","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Acquires all US assets for Ameluz and RhodoLED including NDA and patents from Biofrontera AG.","Effective royalty rate reduced from 25-35% of net sales to 12% (15% above $65M revenue).","Receives $11M investment led by Rosalind Advisors and AIGH Capital Management, funding to profitability.","Biofrontera AG to receive 10% post-money equity stake in Biofrontera Inc., aligning long-term interests.","First tranche of $8.5M funded at signing; second tranche of $2.5M due upon final asset transfer agreement by Sep 30, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161654,"accession_number":"0001641172-25-015584","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-06-18T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biofrontera shareholders approve doubling authorized shares to 70M at annual meeting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Heikki Lanckriet elected Class I director with 4,565,450 votes for, 329,105 withheld.","Amendment to increase authorized common shares from 35M to 70M approved (5,499,898 for, 837,939 against).","Adjournment proposal approved (5,716,131 for) to allow further solicitation if needed.","Ratification of CBIZ CPAs P.C. as auditor for FY2025 approved (6,144,222 for)."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.15,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161653,"accession_number":"0001641172-25-014674","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-06-11T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biofrontera confirms talks with Biofrontera AG on merger or license restructuring","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Negotiations with Biofrontera AG include possible combination of the two companies.","Alternative: adjustment to license/supply agreement transferring certain rights to Biofrontera Inc.","Potential reduction in transfer price for licensed products sold in the US.","Terms not yet established; subject to definitive agreements and conditions.","Disclosure follows June 10, 2025 announcement by Biofrontera AG's management board."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161652,"accession_number":"0001641172-25-013491","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-06-03T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Biofrontera supplements proxy statement reclassifying two proposals as routine matters for broker voting","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["NYSE determined Proposal Nos. 2 and 3 are routine; brokers may vote without instructions, reversing earlier disclosure.","Proposal No. 2 increases authorized common shares from 35M to 70M; Proposal No. 3 is an adjournment measure.","Proxies already received remain valid unless revoked; annual meeting still set for June 12, 2025.","Only Proposal No. 4 (ratification of auditor) was previously listed as routine in the original proxy statement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161651,"accession_number":"0001641172-25-012285","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-05-23T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biofrontera receives Nasdaq deficiency notice for equity below $2.5M","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Stockholders' equity at $469,000, well below Nasdaq's $2.5M minimum requirement.","Company has 45 days to submit a compliance plan to Nasdaq.","If plan accepted, Nasdaq may grant up to 180 days from May 21, 2025 to regain compliance.","Alternative market value or net income criteria also not met."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161650,"accession_number":"0001641172-25-011069","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biofrontera Q1 2025 revenue $8.6M (+9% YoY); net loss narrows to $4.2M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $8.6M, +8.7% YoY; net loss $4.2M ($0.47 per share) vs $10.4M ($2.88) prior year.","Cash and equivalents $1.8M at March 31, 2025, down from $5.9M at Dec 31, 2024.","Phase 3 trial for Ameluz in actinic keratoses on extremities, neck and trunk enrolled final patient; Phase 3 sBCC study completed 1-year follow-up.","Phase 2b study for Ameluz in moderate to severe acne vulgaris completed patient enrollment.","Patent approval extended Ameluz protection to December 2043 for revised formulation."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":8588000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161649,"accession_number":"0001641172-25-010330","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-05-14T23:59:59+00:00","items":["3.01"],"status":"ready","headline":"Biofrontera receives Nasdaq bid price deficiency notice, 180 days to cure","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Nasdaq notified Biofrontera on May 8, 2025 that common stock bid price closed below $1.00 for 33 consecutive business days.","Company has until November 5, 2025 to regain compliance by closing at $1.00+ for 10 consecutive business days.","If not compliant by deadline, company may seek additional time via reverse stock split or face potential delisting.","Management will monitor bid price and consider available options; no assurance of regaining compliance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":161648,"accession_number":"0001641172-25-005428","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-04-18T23:59:59+00:00","items":["4.01","9.01"],"status":"ready","headline":"Biofrontera engages CBIZ CPAs as new auditor after Marcum's resignation tied to acquisition","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum LLP resigned as auditor on April 17, 2025 after CBIZ CPAs acquired its attest business.","Biofrontera's audit committee approved engaging CBIZ CPAs as independent auditor for fiscal 2025.","Marcum's audit reports for 2024 and 2023 had no adverse opinion but included a going concern explanatory paragraph.","No reportable disagreements or events occurred with Marcum during the fiscal years 2024 and 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":179763,"accession_number":"0001493152-25-011083","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2025-03-21T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biofrontera reports record FY 2024 revenue $37.3M, up 9.5% YoY; Q4 net loss $1.4M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record total revenues $37.3M for 2024, +9.5% from $34.1M in 2023; Q4 revenues $12.6M, +18.5% YoY.","Q4 2024 net loss $1.4M ($0.19/share) vs net income $3.5M ($1.65/share) in Q4 2023 due to prior-year legal settlement gain.","Cash and equivalents $5.9M at Dec 31, 2024 vs $1.3M at Dec 31, 2023; Ameluz transfer price reduced from 50% to 25% through 2025.","Placed 100 RhodoLED XL lamps since June 2024 launch; FDA approved up to 3 tubes of Ameluz per treatment.","Phase 3 Study for Ameluz-PDT in superficial BCC achieved statistically significant results; initiated Phase 1 PK study for AK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196531,"accession_number":"0001493152-24-047928","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-11-27T23:59:59+00:00","items":["1.01","2.03","3.01","9.01"],"status":"ready","headline":"Biofrontera issues $4.2M in 10% secured convertible notes due 2027","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["$4.2M private placement of 10% Senior Secured Convertible Notes due Nov 22, 2027 to principal stockholders.","Notes convertible at $0.78/share; automatic conversion if 10-day VWAP exceeds $2.50.","Interest at 10% payable quarterly by increasing principal; rises to 15% on default.","Notes secured by substantially all assets; proceeds for operations and strategic initiatives.","No company redemption option; holder may require repurchase at 100% principal plus interest upon default."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196530,"accession_number":"0001493152-24-047306","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-11-22T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biofrontera closes $4.2M senior secured convertible note with majority shareholders","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Note principal $4.2M, matures Nov 22, 2027; 10% PIK interest; secured by company assets.","Convertible at $0.78/share at holder's option; automatic if 10-day VWAP > $2.50 and conditions met.","Proceeds to support general operations and strategic investments for 2025 growth.","Covenants restrict liens, dividends, indebtedness, and affiliate transactions subject to exceptions."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196529,"accession_number":"0001493152-24-045205","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-11-13T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biofrontera Q3 revenue $9.0M (+1.5% YoY); net loss narrows; FDA approves higher Ameluz dosage","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q3 2024 revenue $9.0M, up 1.5% YoY (would have been +19% without Hurricane Milton delays of ~$1.5M).","Net loss narrowed to $5.7M from $6.3M YoY; adjusted EBITDA -$4.6M vs -$3.9M.","FDA approved sNDA on Oct 4 to increase max Ameluz dosage from one to three tubes per treatment.","Phase 3 sBCC study met all endpoints: 75.9% histological clearance vs 19% placebo (p<0.0001); FDA filing expected H1 2025.","Cash and equivalents $2.9M at Sep 30, up from $1.3M at Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.39,"consensus_revenue_estimate":null,"consensus_revenue_actual":24762000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196528,"accession_number":"0001493152-24-043187","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-10-31T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biofrontera reports Phase 3 sBCC study success; Ameluz-PDT primary endpoint met p<0.0001","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Primary endpoint: 65.5% complete clearance vs 4.8% placebo (p<0.0001); histological clearance 75.9% vs 19.0%.","Total clearance of all sBCC lesions: 64.1% vs 4.8% (p<0.0001); clinical clearance 83.4% vs 21.4%.","FDA dossier submission expected around end of Q2/early Q3 2025 after 12-month follow-up ends Dec 2024.","Study enrolled 187 patients; double-blind, randomized, placebo-controlled, multi-center design.","BCC is most common skin cancer in US (~3.6M cases/year); sBCC is a subset with limited non-invasive options."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":196527,"accession_number":"0001493152-24-039652","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-10-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"FDA approves Biofrontera's sNDA for up to 3 tubes of Ameluz per treatment","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA increased max dosage from 1 to 3 tubes of Ameluz per PDT treatment for actinic keratosis.","Approval supported by two Phase 1 safety studies (116 patients) showing equivalent safety profile.","CEO notes work with Medicare and commercial payers to obtain reimbursement for label update.","AK affects ~58M people in US; ~13M treatments annually; up to 60% of SCCs start as untreated AK."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":212833,"accession_number":"0001493152-24-032328","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-08-14T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biofrontera Q2 revenue $7.8M (+34% YoY); net loss narrows to $0.3M from $9.8M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2024 total revenues $7.8M, up 34% from $5.8M in Q2 2023; catch-up from lower 1Q sales due to Change Healthcare cyber event.","Net loss improved to $257K from $9.8M; adjusted EBITDA -$4.7M vs -$7.9M in prior year.","Cash and equivalents $4.4M at June 30, 2024, up from $1.3M at Dec 31, 2023; raised $8.0M from May 2024 warrant exercises.","Launched FDA-approved RhodoLED XL lamp in June; shipped first three machines within one week of launch.","Took control of all US clinical trials for Ameluz on June 1, 2024, under amended license agreement to reduce costs."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":15750000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231890,"accession_number":"0001493152-24-024881","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-06-24T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Biofrontera launches FDA-approved RhodoLED XL lamp for PDT of actinic keratoses","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["RhodoLED XL is FDA-approved for use with Ameluz (aminolevulinic acid) for mild-to-moderate actinic keratoses on face and scalp.","Commercial distribution launched June 10, 2024; first three machines shipped within one week.","Larger illumination area: five panels vs one on prior lamp; includes positioning sensors for optimal energy delivery.","First customer Cleaver Dermatology (MO and GA) installed the XL lamp; response from dermatology organizations is positive."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231889,"accession_number":"0001493152-24-023888","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-06-14T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"Stockholders approve amendment to 2021 Omnibus Incentive Plan, increasing authorized shares from 266,990 to 3,750,000","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Stockholders approved amendment to Plan to increase authorized shares by 3,483,010, from 266,990 to 3,750,000.","John J. Borer III and Prof. Hermann Luebbert were elected as Class III directors for term until 2027 Annual Meeting.","Marcum LLP ratified as independent registered public accounting firm for fiscal year ending Dec. 31, 2024.","Total votes cast: 2,759,226 shares representing a quorum present at the meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231888,"accession_number":"0001493152-24-021019","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-05-22T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Biofrontera regains Nasdaq compliance on stockholders' equity rule; future warning","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["May 17, 2024 Nasdaq notice confirms compliance with Rule 5550(b)(1) based on Q1 2024 10-Q.","Prior non-compliance disclosed Nov 2023 due to stockholders' equity deficiency in Q3 2023.","Notice cautions that failure to maintain compliance in next periodic report may result in delisting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231887,"accession_number":"0001493152-24-020031","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-05-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biofrontera Q1 revenue down 9% to $7.9M; net loss $10.4M; Ameluz license renegotiated","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $7.9M, down 9% YoY from $8.7M due to Change Healthcare data breach reimbursement issues.","Net loss $10.4M ($2.88 per share) vs $7.5M ($5.60 per share) in prior year; loss per share improved due to share count increase.","Cash $3.8M at quarter end vs $1.3M at Dec 31, 2023; raised $8M via preferred placement plus $8M via warrant exercises.","Renegotiated Ameluz transfer price to 25% for 2024-2025 (down from 40-50%) and will assume US clinical trial management from June 1.","FDA accepted sNDA for Ameluz dosage from 1 to 3 tubes; final decision expected by Oct 4, 2024; new RhodoLED XL lamp sales expected Q2 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.88,"consensus_revenue_estimate":null,"consensus_revenue_actual":7912000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231886,"accession_number":"0001493152-24-017641","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-05-03T23:59:59+00:00","items":["7.01","8.01","9.01"],"status":"ready","headline":"Biofrontera achieves milestones on Series B-3 warrants, unlocking $8M gross proceeds","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board certified >5% YoY revenue growth (Jan-Apr 2024 vs 2023, ex-related parties) and >95% CRM adoption.","Warrant exercise triggers $8M gross proceeds to Biofrontera.","Shareholders approved authorized share increase from 15M to 35M at April 24 special meeting.","Warrants expiration now 5 days after S-1 effectiveness (filed May 2) or Feb 22, 2027."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231885,"accession_number":"0001493152-24-017255","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-04-30T23:59:59+00:00","items":["5.03","9.01"],"status":"ready","headline":"Biofrontera increases authorized common shares from 15M to 35M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Authorized common shares increased from 15,000,000 to 35,000,000 via Certificate of Second Amendment.","Amendment filed with Delaware Secretary of State on April 25, 2024.","Stockholders approved the increase at a Special Meeting held April 24, 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.45,"calibrated_materiality_score":0.45,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231884,"accession_number":"0001493152-24-015949","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-04-25T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"Biofrontera shareholders approve increase in authorized common stock from 15M to 35M shares","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Proposal 1 passed with 3,417,559 for, 230,822 against, 4,019 abstain; quorum of 3,652,400 votes.","Proposal 2 (adjournment) passed with 3,499,401 for, 141,928 against, 11,071 abstain.","Authorized shares doubled to 35,000,000 from 15,000,000 via charter amendment.","Special Meeting held April 24, 2024; no solicitation opposition."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":231883,"accession_number":"0001493152-24-013031","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K/A","filed_at":"2024-04-03T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"Biofrontera moves annual meeting record date from Apr 22 to Apr 15, 2024","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Original record date of April 22, 2024 changed to April 15, 2024.","Annual meeting remains scheduled for June 12, 2024.","No other changes from the March 26, 2024 Form 8-K."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250182,"accession_number":"0001493152-24-011323","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-03-26T23:59:59+00:00","items":["5.08","8.01","9.01"],"status":"ready","headline":"Biofrontera sets 2024 Annual Meeting for June 12; updates proxy proposal deadlines","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Annual meeting of stockholders set for June 12, 2024; record date is April 22, 2024.","Deadline for stockholder proposals to be included in proxy statement (Rule 14a-8) is April 19, 2024.","Deadline for director nominations and proposals under bylaws (not for proxy inclusion) is April 5, 2024.","Previous deadlines superseded because 2024 meeting date is more than 30 days before 2023 meeting anniversary."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":250181,"accession_number":"0001493152-24-010152","cik":1858685,"company_name":"Biofrontera Inc.","ticker":"BFRI","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Biofrontera reports record FY2023 revenue of $34.1M, +19% YoY; Q4 net income $3.5M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["FY2023 total revenues $34.1M (+19% YoY); operating expenses $56.7M (incl $2M one-time legal).","Q4 2023 revenue $10.6M (+4% YoY); net income $3.5M ($1.65/shr) vs loss $2.8M ($2.16 loss/shr) in Q4 2022.","Adjusted EBITDA for Q4 negative $3.2M (improved from negative $4.4M in prior year).","Submitted sNDA to increase Ameluz use to 3 tubes for AK; PDUFA Oct 4, 2024. Phase 3 enrollment for sBCC completed.","Restructured LSA to cut transfer price to 25% for 2024-2025; acquired patents for new portable PDT lamp."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":10985269.713207545,"market_cap_bucket":"microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}